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Introduction
Bone resorption is an essential component of bone remodeling during the development, growth and turnover of bone. An imbalance contributes to the pathogenesis as well as the etiology of metabolic diseases such as osteoporosis and osteopetrosis (Eriksen, 1986; Rodan and Martin, 2000; Boyle et al, 2003) . Osteoclasts are multinuclear cells originating from monocyte/macrophage lineage cells and are primarily responsible for bone resorption (Baron et al, 1994; Blair, 1998; Väänänen et al, 2000) . During the resorption process, osteoclasts are highly polarized, form tightly sealed compartments (i.
e., resorption lacunae) on the bone surface, and secrete protons, chloride anions and proteases through the ruffled border, resulting in the degradation of the bone matrix.
To transport a large amount of degradation products, osteoclasts develop an inwardly polarized membrane traffic called transcytosis: inorganic and organic degradation products and cathepsin K are taken up at the ruffled border through endocytosis, packaged into transcytotic vesicles, transported along microtubules to the basolateral plasma membrane, and then secreted through exocytosis (Nesbitt and Horton, 1997; Salo et al, 1997; Mulari et al, 2003) . The overall secretory processes are believed to be highly organized and coordinated with other bone functions, although the mechanisms and regulation of transcytosis remain poorly understood.
L-Glutamate, an excitatory neurotransmitter of the central nervous system, acts as an intercellular messenger in peripheral non-neuronal cells, in which L-glutamate is stored in secretory vesicles and secreted through regulated exocytosis and, thus, enables intercellular chemical transmission in a paracrine-or autocrine manner (Moriyama and Yamamoto, 2004) . Although there is evidence for L-glutamate signaling in bone, its physiological significance has not been established (Serre et al, 1999; Bhangu et al, 2001; Hinoi et al, 2001; Skerry and Taylor, 2001; Mason, 2004) . Bone cells express the GLAST-type Na + -dependent plasma membrane transporter, which terminates L-glutamate signals (Skerry and Taylor, 2001; Mason, 2004) . Bone cells also express various functional glutamate receptors, and their stimulation affect the functions of osteoblasts and osteoclasts (Skerry and Taylor, 2001; Mason, 2004) . However, it is still unresolved where, when and how L-glutamate appears as an intercellular messenger in bone. Although L-glutamate has been suggested to originate from L-glutamate-containing nerve terminals (Serre et al, 1999) or osteoblasts (Bhangu et al, 2001; Hinoi et al, 2002) , secretion of L-glutamate from nerve terminals has not been detected. Furthermore, the mode of secretion of L-glutamate from osteoblasts differs from that of the exocytosis of L-glutamate in CNS or endocrine cells.
Vesicular glutamate transporter (VGLUT) plays an essential role in L-glutamate signaling through vesicular storage of L-glutamate (Fremeau et al, 2004a; Moriyama and Yamamoto, 2004) . There are three isoforms of VGLUT: VGLUT1, VGLUT2 and VGLUT3. VGLUT is a potential marker for the sites of L-glutamate signaling and can help reveal details of the mode of glutamate signaling in the body (Moriyama and Yamamoto, 2004) .
In the present study, we examined the expression and localization of VGLUT in bone tissue to determine how L-glutamate becomes an intercellular messenger. We found an unexpected link between L-glutamate signaling and bone resorption. We 
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RT-PCR analysis demonstrated that osteoclasts derived from bone marrow cells contained mRNA encoding VGLUT1 and that other types of bone cells including primary osteoblasts, stroma cells and clonal bone cells did not express this mRNA ( Figure 1A ). Neither VGLUT2 nor VGLUT3 was expressed in any of the bone cells analyzed ( Figure 1B ). Northern blot analysis revealed mRNA of VGLUT1 in mature osteoclasts but not in undifferentiated cells ( Figure 1C ). Upon stimulation with RANKL, a receptor activator of the nuclear factor κB ligand, murine macrophage RAW 264.7 cells can differentiate into osteoclasts (Toyomura et al, 2003) that then express the VGLUT1 gene ( Figure 1A , C). These results indicate that the VGLUT1 gene was specifically expressed in osteoclasts during differentiation and that expression of the VGLUT2 and VGLUT3 genes in bone cells was negligible or below the detection limit of our assay.
Immunoblotting with VGLUT1 antibodies revealed that an immunoreactive polypeptide with an apparent molecular mass similar to that of VGLUT1 (~62 kDa) appeared in RAW264.7 cells upon treatment of RANKL, while expression of the housekeeping vacuolar H + -ATPase (V-ATPase) subunit was the same before and after differentiation ( Figure 1D ).
Inducible expression of VGLUT1 immunoreactivity in RAW264.7 cells treated with RANKL was confirmed by immunohistochemistry: VGLUT1 immunoreactivity appeared three days after induction and reached a steady state level after seven days ( Figure 1E ). The presence of VGLUT1 immunoreactivity in tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts was confirmed in the femurs of VGLUT1 +/+ (wild type) mice but not in those of VGLUT1 -/-mice ( Figure 1F ). Essentially the same results were obtained in osteoclasts prepared from VGLUT1 +/+ (wild type) mice but not in those of VGLUT1 -/-mice (supplementary information, Figure S1 ). Overall, these results demonstrate that VGLUT1 appeared in osteoclasts during osteoclastogenesis.
VGLUT1 was associated with transcytotic vesicles
To identify VGLUT1-containing organelles, we performed immunohistochemical analyses.
After culturing on bone, an actin ring was observed, indicating the site of bone digestion (Figure 2A ). The VGLUT1 immunoreactivity exhibited a punctated distribution throughout the cells and was especially abundant in the basolateral region, but less in the ruffled border region (Figure 2A, B) . VGLUT1 was roughly co-localized with microtubules but not with actin ( Figure 2A, B) . VGLUT1 did not seem to be co-localized with Lamp2, TGN38, GM130 or transferrin receptor (TfR), which are markers for lysosomes, the Golgi apparatus, endosomes and recycling vesicles, respectively (supplementary information, Figure S2 ), but rather was partially co-localized with lysobisphosphatidic acid, a phospholipid abundant in late endosomes ( Figure 2C ) and cathepsin K ( Figure 2D ), both of which are associated with the transcytotic pathway after endocytosis (Vääräniemi et al, 2004) . Furthermore, VGLUT1 immunoreactivity was, in part, co-localized with the internalized fluorescent bone degradation products ( Figure 2E ). These results suggest that VGLUT1 was associated with the vesicles involved in the transcytotic pathway, such as transcytotic vesicles.
VGLUT1-containing vesicles were identified through double immunoelectron microscopy. Consistent with the immunohistochemical observations made above, there were at least three types of vesicles associated with immunogold particles specific for VGLUT1 and bone degradation products: many clear vesicles with an average diameter of ~300 nm in which VGLUT1 was present but in which immunoreactivity for bone degradation products was not detected ( Figure 3A) , larger vesicles located near basolateral regions that contained many VGLUT1 immunogold particles and some particles for bone degradation products ( Figure 3B ), and larger vesicles located near the ruffled border membrane that contained many immunogold particles for bone degradation products and a few immunogold particles for VGLUT1 ( Figure 3C ). We concluded that a population of VGLUT1 was associated with the transcytotic vesicles that contain bone degradation products. The dynamics of these vesicles during transcytosis is discussed later.
VGLUT1 in osteoclasts was functional
We then determined whether VGLUT1-containing vesicles accumulate L-glutamate.
Generally, V-ATPase supplies the driving force for the vesicular storage of L-glutamate (Maycox et al, 1990; Moriyama and Yamamoto, 2004) . We prepared membrane vesicles 
Osteoclasts secreted L-glutamate through transcytosis
Do osteoclasts secrete L-glutamate? Since the exocytosis of L-glutamate is usually driven by membrane depolarization, we measured the L-glutamate present in the medium after depolarization of osteoclasts with KCl. KCl at 50 mM depolarizes bone-resorbing osteoclasts through a voltage-gated K + channel (Kajiya et al, 2003) . We found that KCl Figure   5B ). These properties are similar to those reported for the regulated exocytosis of L-glutamate by neurons and endocrine cells (Moriyama and Yamamoto, 2004) .
Since a population of VGLUT1 is associated with transcytotic vesicles, secretion of L-glutamate may accompany, at least in part, the secretion of bone degradation products.
As expected, KCl stimulated secretion of fluorescent bone degradation products ( Figure   5C ). The secretion also required extracellular Ca 2+ and was sensitive to temperature and bafilomycin A1 ( Figure 5C ). Bafilomycin A1 is also known to inhibit transcytosis (Palokangas et al, 1997; Stenbeck and Horton, 2004) . Furthermore, nocodazole, a reagent that dissociates microtubules and, through this, inhibits transcytosis (Stenbeck and Horton, 2004) , inhibited the secretion of both L-glutamate and bone degradation products to a similar extent ( Figure 5B , C). These results support the idea that L-glutamate was co-secreted with bone degradation products through transcytosis.
It is important to ask what kinds of stimuli trigger transcytosis under physiological conditions. We found that ATP at 1 mM stimulated the secretion of both L-glutamate ( Figure 5D ) and bone degradation products ( Figure 5E ), and was blocked by pyridoxalphosphate-6-azophenyl-2'-4'-disulfonic acid (PPADS), a selective antagonist of ionotropic purinergic receptors (Ralevic and Burnstock, 1998) . Since ATP is secreted from osteoblasts upon mechanical stimulation and depolarizes osteoclasts so as to increase the cytosolic concentration of Ca 2+ via ionotropic purinergic receptors (Naemsch et al, 2001; Romanello et al, 2001) , the results suggest that ATP was one of the physiological stimuli for secretion of L-glutamate and bone degradation products.
L-Glutamate secretion from osteoclasts from VGLUT1 -/-mice
We then assessed L-glutamate secretion from osteoclasts prepared from VGLUT1 -/-mice.
The number and morphology of osteoclasts from VGLUT1 +/-heterozygotes and VGLUT1 -/-homozygotes were apparently comparable to those of wild type osteoclasts. As shown in Figure 6 A and B, KCl stimulated the secretion of L-glutamate in osteoclasts from wild type and heterozygotic mice by a factor of ~2. The KCl-evoked secretion of L-glutamate was not observed in the case of osteoclasts from VGLUT1 -/-homozygotes ( Figure 6C ). Essentially the same results were obtained when the L-glutamate secretion was evoked by ATP ( Figure   6D ). In contrast to the L-glutamate secretion, KCl-mediated secretion of bone degradation products was not altered in osteoclasts of all three mice genotypes ( Figure 6E ).
mGluR8-mediated autoregulation of transcytosis
Subsequently, we investigated the role of the released L-glutamate. Since L-glutamate signaling in peripheral tissues usually involves an autoregulatory mechanism by way of metabotropic receptors (Yamada et al, 1998; Uehara et al, 2004) , we investigated whether mGluRs are expressed in osteoclasts, and if so, whether they regulate transcytosis. Among known mGluRs, RT-PCR indicated the presence of mRNAs of mGluR3, mGluR4 and mGluR8 in RAW 264.7 cells treated with RANKL and the presence of mGluR3, mGluR5 and mGluR8 in osteoclasts ( Figure 7A and supplementary information, Figure S3 ).
Immunoreactivity for mGluR8 ( Figure 7B ), but not mGluR3 and mGluR4 was detected by immunohistochemical analysis in RAW264.7 cells treated with RANKL (data not shown), suggesting expression of mGluR8 in mature osteoclasts.
It is important to ask whether mGluR8 regulates transcytosis. Upon the addition of (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I), a specific agonist of class III mGluRs (Acher et al, 1997) , KCl-evoked secretions of both L-glutamate and bone degradation products decreased by about 90% and 87% of the control, respectively, and the inhibitions were blocked by the (R,S)-cyclopropyl-4-phosphonophenylglycine (CPPG), a specific antagonist (Toms et al, 1996) and dibutylylcAMP (DBcAMP), a non-hydrolyzable cAMP analogue ( Figure 7C, D) . Agonists for other mGluRs and NMDA receptor did not affect the secretions of L-glutamate (data not shown). mGluR8 is functionally coupled with the Gi protein, and thus its stimulation decreases intracellular cAMP content (Nakanishi, 1992) . Consistent with these observations, both ACPT-I and L-glutamate decreased cAMP content, which were fully recovered by CPPG ( Figure 7E ). These results are consistent with the idea that mGluR8 was functionally expressed in mature osteoclasts and inhibited transcytosis through an inhibitory cAMP cascade.
Blocking the glutamate signal stimulates the resorptive activity of osteoclasts
To reveal the physiological relevance of L-glutamate-mediated autoregulation of transcytosis, we investigated whether blocking the L-glutamate signaling with CPPG affects bone resorption. We monitored the area of bone resorption produced by osteoclasts on dentine slices as a functional marker for osteoclasts. α-MEM contains 0.5 mM L-glutamate, the concentration at which L-glutamate mediated autosuppression of transcytosis may occur. Thus, under the culture conditions, CPPG stimulated the bone resorptive activity by 1.5 fold (Figure 8) . Eel calcitonin at 10 nM inhibited bone resorption (Figure 8 ). These results suggest that blocking the glutamate signal stimulated bone resorptive activity by osteoclasts.
Finally, to determine whether preventing L-glutamate signaling causes phenotypic changes in the bone tissues, we assessed the bone mass of female VGLUT1 -/-mice using microCT. Comparing the bone masses in wild type and homozygotes, the bone mass, expressed as a ratio of BV/TV, of homozygotes had decreased and was significantly lower by the age of 4 months and exhibited osteoporosis-like symptoms (Figure 9 ). Essentially the same results were obtained in all homozygotes tested (n = 3).
Discussion
The present results demonstrated that bone-resorbing osteoclasts were the site of L-glutamate signaling. Osteoclasts exhibited a glutamatergic phenotype upon maturation. Functional VGLUT1 was inducibly expressed in osteoclasts as demonstrated by molecular biological, biochemical and immunohistochemical techniques. VGLUT1 was associated with small clear vesicles and larger membrane vesicles that also contained bone degradation products (Figures 2 and 3) . L-Glutamate and bone degradation products were secreted through transcytosis. L-Glutamate was not stored in vesicles of osteoclasts prepared from VGLUT1 -/-mice.
Consequently, osteoclasts prepared from VGLUT1 -/-mice did not secrete L-glutamate. These results provided convincing evidence for the glutamatergic nature of osteoclasts.
Up until now transcytosis of bone degradation products has been characterized primarily by morphological methods (Nesbitt and Horton, 1997; Salo et al, 1997; Mulari et al, 2003) . Little is known about the mechanism of transcytosis. Since some of VGLUT1 molecules were associated with transcytotic vesicles, we thus hypothesized that L-glutamate is co-localized and co-secreted with bone degradation products through transcytosis.
Experiments were performed to characterize the secretion of L-glutamate and bone degradation products. The secretion of both was found to require, at least partially, the influx of extracellular Ca 2+ . Moreover, inhibition of both secretory activities by a class III mGluR agonist, and the reversion of this effect with a specific antagonist suggested the requirement of cAMP for both secretion processes (Figure 7) . Thus, secretion of L-glutamate and bone degradation products apparently involves regulated exocytotic processes that are similar to that in neurons and endocrine cells. In addition, both secretory activities showed similar temperature dependence and sensitivities to bafilomycin A1 and nocodazole. These results constitute evidence that L-glutamate and bone degradation products are secreted together through transcytosis. To our knowledge, this is the first direct evidence that transcytosis contains a regulated process. Presence of a regulated process in transcytosis suggests involvement of molecular machinery similar to that of the exocytotic pathway of neuronal synaptic vesicles and endocrine secretory granules. Identification of molecular components involved in the transcytosis such as soluble
N-ethylmaleimide-sensitive attachment protein receptor (SNARE)-like proteins and
voltage-gated Ca 2+ channels in bone resorbing osteoclasts is urgently needed for full characterization of the regulated transcytosis.
Another important feature of transcytosis is the involvement of an ionotropic purinergic P2 receptor(s) in the process. Osteoclasts as well as osteoblasts express multiple P2 receptor subtypes and an increasing amount of evidence has highlighted the importance of P2 receptors in the bone microenvironment and the bone remodeling processes (Gallagher and Buckley, 2002; Gartland et al, 2003) . Which P2 subtype triggers secretion of L-glutamate and bone degradation products is unknown and awaits further study. Since ATP is released from osteoblasts upon mechanical stimulation (Romanello et al, 2001; Jørgensen et al, 2002) , our results suggest that osteoblasts affect transcytosis of osteoclasts through ATP-and L-glutamate signaling pathways.
We propose the following secretory events during bone resorption: osteoclasts absorb bone degradation products through endocytosis and sequester them in transcytotic vesicles. Afterwards, VGLUT1-containing vesicles (small clear vesicles shown in Figure   3A ) fuse with transcytotic vesicles and the resultant vesicles store both L-glutamate and bone degradation products (larger vesicles seen in Figure 3B ). Subsequently, L-glutamate and other internal materials are secreted together through exocytosis ( Figure 10, left panel) . In osteoclasts of VGLUT1 -/-mice, transcytotic vesicles apparently fused with vesicles containing no L-glutamate, which led to the secretion of bone degradation product without concomitant release of L-glutamate ( Figure 10, right panel) . Thus, the secretory pathways for L-glutamate and bone degradation products overlapped, but were not dependent upon one another. One can ask whether L-glutamate secretion is, at least in part, mediated through another secretory mechanism other than transcytosis, since the proportion of VGLUT1 associated with transcytotic vesicles is not known. This possibility seems to be unlikely, however, because the secretion of L-glutamate and bone degradation products shared similar biochemical and pharmacological characteristics as described above. More detailed and 13 quantitative study will clarify this issue. In any event, transcytosis of L-glutamate and bone degradation products appears to be a more complex secretory event than previously thought.
We have provided evidence that L-glutamate and bone degradation products were secreted through transcytosis. Through this, L-glutamate may act in a paracrine/autocrine manner, allowing regulation of cellular function and/or differentiation by way of glutamate receptors (Mason, 2004) . In our studies, we found that mGluR8 decreased cAMP content and inhibited KCl-evoked secretion of L-glutamate and bone degradation products. Thus, L-glutamate secreted through transcytosis may be involved in the negative feedback cascade for transcytosis ( Figure 10 ). This is reminiscent of L-glutamate signaling in pineal glands (Yamada et al, 1998) and islet of Langerhans (Uehara et al, 2004 ) that leads to the inhibition of melatonin synthesis and glucagon secretion by way of mGluR2/3 and mGluR4, respectively. mGluR-coupled autoregulation may be a common feature of L-glutamate signaling in the peripheral tissue.
One of the significant findings in the present study is that VGLUT1 -/-mice develop osteoporosis four months after birth (Figure 9 ). Since glutamate signaling may involve a negative feedback regulation of transcytosis as described above, under normal physiological conditions, bone resorption should be suppressed by L-glutamate signaling. The fact that blocking the L-glutamate-mediated autoregulatory cascade by an mGluR8 antagonist enhanced bone resorption supports this idea (Figure 8 ). In osteoclasts of VGLUT1 -/-mice the loss of the ability to secrete L-glutamate did not affect secretion of bone degradation products ( Figure 6E ). Thus, the negative feedback regulation in osteoclasts is impaired in VGLUT1 -/-mice, leaving the osteoclasts in a desuppressed state that led to elevated bone resorption that, in turn, led to osteoporosis (Figure 10 , right panel). Since purinergic stimulation facilitates L-glutamate secretion ( Figure 5 ), it is expected that inhibition of purinergic signaling causes similar effects on osteoclastic activity. In this respect, it is noteworthy that deletion of the ionotropic P2X7 receptor causes increased trabecular bone resorption (Ke et al, 2003) . To our knowledge, this is the first report presenting direct 14 evidence that impairment of glutamate signaling is associated with a metabolic disorder.
Further studies, especially quantitative analyses as to interrelationship among glutamate signaling, transcytosis of bone degradation products and bone digestion, are necessary to elucidate the detailed signaling cascade and how impairment of glutamate signaling leads to osteoporosis.
The finding that transcytotic vesicles serve as storage organelles for L-glutamate expands the concept of the glutamate signaling. In addition to neuronal synaptic vesicles, we have shown that VGLUTs are functionally associated with synaptic-like microvesicles in pinealocytes, hormone-containing secretory granules in islet α and F cells and intestinal L cells, and acrosomes of early spermatid (Moriyama and Yamamoto, 2004; Uehara et al, 2006) . In conclusion, we have clarified the issues of when, where and how L-glutamate is secreted in bone tissues. Glutamatergic signal transmission may play essential regulatory role(s) in bone homeostasis, since impairment of L-glutamate signaling stimulates bone resorptive activity, leading to osteoporosis.
Materials and methods
Cell cultures
Primary osteoblasts were prepared from newborn ddY mice by sequential enzymatic digestion as previously described (Suda et al, 1997) . Osteoclasts were induced to differentiate into mature osteoclasts by the co-culture method described by Suda et al (1997) with slight modifications. More than 90% of the adherent cells were TRAP-positive, which were used for experiments after prolonged incubation. To differentiation of osteoclasts from RAW 264.7 cells, the cells were treated with 100 ng/ml extracellular domain of RANKL (sRANKL) (Peprotech EC) and 10,000 units/ml macrophage colony-stimulating factor (Kyowa Hakko) as described (Toyomura et al, 2003) .
Primary osteoblasts and clonal bone cell lines including MC3T3-E1, MC3T3-G2/PA6, ST2 (Udagawa et al, 1989) and C3H10T1/2 (Levine and Teegarden, 2004) were cultured as described.
VGLUT1 knockout (-/-) mice
A line of VGLUT1 -/-mice was maintained as heterozygotes by continuous backcrossing with wild type +/+ C57/BL6 mice as described (Fremeau et al, 2004b) . Mice were genotyped by PCR (Fremeau et al, 2004b) before use.
Reverse transcription polymerase chain reaction (RT-PCR) and Northern analysis
Total RNA (1 µg) extracted from cultured cells was transcribed into cDNA in a final volume of 20 µl of a reaction buffer containing 0.2 mM each dNTP, 10 mM dithiothreitol, 100 pmol of random octamers, and 200 units of Moloney murine leukemia virus reverse transcriptase (Amersham). After 1 h incubation at 42 °C , the reaction was terminated by heating at 90 °C for 5 min. The PCR amplification was performed as described (Hayashi et al, 2003a) . The sequences of the oligonucleotides used as primers were based on the published sequences, and are shown in the supplementary Table IS. DNA sequencing was performed by the chain termination method. For Northern blotting, the mRNA (4.5 µg per lane) was separated on a 1% agarose gel containing formaldehyde and then transferred to a nylon membrane (Amersham). The immobilized RNA was probed with cDNA fragments of VGLUT (nt 270 -706) labeled with [ 32 P]-dCTP (3000 Ci/mmol, Amersham) by random priming. After extensive washing, the membrane was subjected to autoradiography using BAS 1000 film (Fuji Film Co.).
Antibodies
Site-specific polyclonal antibodies against rat VGLUT1, V-ATPase subunit A and mGluR4 were prepared; their immunological specificities have been described elsewhere (Hayashi et al, 2003b; Uehara et al, 2004) . Guinea pig polyclonal antibodies against mGluR8 and rabbit polyclonal antibodies against mGluR2/3 were purchased from Chemicon. The following antibodies were used as organelle markers: mouse monoclonal antibody 6C4
(kindly supplied by Dr. T. Kobayashi, Riken, Wako, Japan); mouse monoclonal antibodies 
Western blotting
Membrane fraction from RAW264.7 cells treated with RANKL or untreated cells (1 × 10 8 cells each) were prepared and denatured with SDS sample buffer containing 1% SDS and 10% β-mercaptoethanol. Then, Western analysis was performed as described in Hayashi et al. (2003a) .
Immunohistochemistry
The procedure of Hayashi et al. (2003a,b) was used. In brief, cells on collagen-coated coverslips were fixed with 4% paraformaldehyde in PBS for 30 min, followed by a 15 min incubation in the PBS containing 0.1% Triton X-100, 2% goat serum and 1% bovine serum albumin (BSA), and finally reacted with antibodies at 1 µg/ml or diluted 1000-fold (anti-VGLUT1 or other antibody) in PBS containing 0.5% BSA for 1 h at room temperature. Samples were washed four times with PBS and then reacted with the secondary antibody for 1 h at room temperature. The secondary antibodies used were Alexa Fluor 568-labeled anti-mouse IgG (1 µg/ml) or Alexa Fluor488-labeled anti-rabbit IgG (2 µg/ml) (Molecular Probes). Finally, the immunoreactivity was examined under an Olympus FV300 confocal laser microscope.
For immunostaining of femur sections, mice were anesthetized with ether and then perfused intracardially with saline, followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The femora were isolated and immersed in the same solution overnight at 4 °C. After washing with PBS, the femora were decalcified with 9% EDTA-2Na and 10% EDTA-4Na in PBS at 4 o C for 1 week. They were successively infiltrated with 30% sucrose in PBS, embedded in OTC compound (Sakura Finetek), sectioned at a thickness of 6 µm, and then mounted on gelatin-coated slides. The immunological reaction was performed as described above. Histochemical staining for TRAP with horseradish peroxidase-diaminobenzidine (HRP-DAB) was performed as described (Nakamura et al, 1994) .
Immunoelectron microscopy
Samples were fixed with 0.2% glutaraldehyde and 4 % paraformaldehyde in 0.1 M phosphate buffer (pH 7.4), dehydrated, and then embedded in LR white for 2 days at -20 °C . Ultrathin sections on nickel grids were incubated with PBS containing 2% goat serum and 2% BSA for 10 min, followed by an incubation with mixture of rabbit anti-VGLUT1 antiserum (diluted 50-fold) and mouse anti-FITC monoclonal antibodies (diluted 125-fold) for 1 h at room temperature, and, finally, an incubation with a mixture of secondary antibodies conjugated with colloidal gold for 15 min at room temperature (Hayashi et al, 2003a) . After washing with 0.1M sodium cacodylate buffer (pH 7.4), the sections were postfixed in 5% glutaraldehyde in the cacodylate buffer, stained sequentially with uranyl acetate for 10 min and lead citrate for 1 min, and observed under a Hitachi H-7100S electron microscope.
L-Glutamate uptake
A membrane fraction of cultured cells was prepared as described above and used for the transport assay within a day of preparation; the samples were not frozen. column (4.6 mm × 150 mm; Waters Ltd.) and fluorescence detection as described previously (Hayashi et al, 2003a) . To measure secretion of bone degradation products, osteoclasts (1.0 × 10 3 cells) were cultured on dentine disks, which were labeled with the seminaphtofluorescein dye 5,6-carboxyl-SNAFL ® -2 (Molecular Probes) as described by Stenbeck and Horton (2004) . After incubation for 12 h, the osteoclasts were stimulated by the addition of either 50 mM KCl or 1 mM ATP (final concentrations). Then, 100
µl medium was carefully sampled and diluted with 1.9 ml glycine-NaOH (pH 10.0) and the fluorescence intensity measured.
Measurement of cAMP
cAMP was quantified with the enzyme immunoassay kit obtained from Cayman Chemical (Ann Arbor , Michigan), according to the manufacture's manual.
Measurement of bone resorption activity
The resorption pit assay was performed as described by Li et al (2002) . Co-cultured osteoclasts on collagen gel-coated dishes were detached with 0.2% collagenase and plated on dentine slices and cultured in α-MEM medium containing 10% FBS in the presence or absence of 100 µM CPPG for 24 h. In control experiments, eel calcitonin (Elcatonin, Asahi Chemical Industry Co. Tokyo) at 10 nM was included. Resorption pits on the dentine slices were visualized by staining with Mayer's hematoxylin, and observed under an Olympus BX60 microscope. To quantify the resorption areas, five areas of dentine slices were randomly selected and stained resorption lacunae were measured with NIH Image program.
Bone morphometry
To assess the parameters for bone morphometry, 8 weeks and 4 months-old VGLUT1
+/+ and VGLUT1 -/-mice were anesthetized with ether and perfused intracardially with saline, followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The femora were then isolated and immersed in the 4 % paraformaldehyde in PBS at 4 °C.
The images were taken by micro focus X-ray computed tomography (ScanXmate-A080, COMSCAN TECNO CO. Ltd.), and reconstituted into 3D images with Fan CT. Ratio of trabecular bone volume to total tissue volume (BV/TV) was calculated with analytic software (TRI/3D BON, Ratoc System Engineering Co. Ltd.) (Sone et al, 2004) . The 20 trabecular bone in the distal metaphysis of the femur was chosen as the sampling site, where was located from 0.5 mm to 1.5 mm from the growth plate.
Data analysis
All numerical values are shown as means + SEM (standard error of the mean). n is the number of experiments. The significance of differences between the mean values of two indicated groups was evaluated with the student's t-test. Statistical evaluations were performed using MS Excel (version 11.0).
